Sander Nancy, Fusco-Walkert Sandra J, Harder Julia M, Chipps Bradley E
Allergy & Asthma Network Mothers of Asthmatics, Fairfax, Virginia, USA.
Ann Allergy Asthma Immunol. 2006 Jul;97(1):34-8. doi: 10.1016/s1081-1206(10)61366-x.
Pressurized metered-dose inhalers (pMDIs) are the cornerstone of asthma treatment. The pMDI is an economic and portable medication delivery system, but the device does not indicate how much medicine remains in the canister once a patient starts using it.
To determine how patients evaluate the contents of their pMDI and whether they are either discarding inhalers when medication remains or using inhalers beyond the indicated number of doses.
This study was conducted in April 2003 via a 6.5-minute telephone interview with a random sample of 500 families with asthma from across the United States.
Of the 500 respondents participating in the telephone interview, nearly one third (31.6%) named an inhaled corticosteroid or bronchodilator and inhaled corticosteroid combination as the inhaler used when wheezing, coughing, or short of breath. Respondents using a bronchodilator (n = 342) varied in the frequency with which they use their pMDIs: 31.9% daily, 18.7% weekly, 23.4% monthly, and 23.1% less than once per month. More than half (53.8%) of bronchodilator users refill their prescriptions more frequently than recommended by national guidelines. Only 36% of bronchodilator users reported ever having been told to keep track of pMDI doses used. Of those, 79% had been advised to do so by a physician, 6% by a pharmacist, and 3% by a nurse. Eighty-seven (25%) of the 342 respondents who named a bronchodilator reported having found their pMDI empty during an asthma exacerbation. Seven of those patients had to call 911. Of these 87 patients, 71 (82%) considered their pMDI empty when absolutely nothing came out.
Patients do not have a reliable means of monitoring the contents of their metered-dose inhalers, which is causing serious problems that need to be addressed. Given the necessity of a reliable dose counting method, it is clear that manufacturers should include dose counters as a standard feature of every metered-dose inhaler.
压力定量吸入器(pMDIs)是哮喘治疗的基石。pMDI是一种经济且便于携带的药物输送系统,但一旦患者开始使用该装置,它不会显示药罐中还剩余多少药物。
确定患者如何评估其pMDI的药物含量,以及他们是否在药物还有剩余时就丢弃吸入器,或者使用超过规定剂量次数的吸入器。
本研究于2003年4月通过对来自美国各地的500个哮喘家庭进行随机抽样,进行6.5分钟的电话访谈来开展。
在参与电话访谈的500名受访者中,近三分之一(31.6%)提到在喘息、咳嗽或呼吸急促时使用吸入性糖皮质激素或支气管扩张剂以及吸入性糖皮质激素组合。使用支气管扩张剂的受访者(n = 342)使用pMDIs的频率各不相同:31.9%每天使用,18.7%每周使用,23.4%每月使用,23.1%每月使用次数少于一次。超过一半(53.8%)的支气管扩张剂使用者比国家指南推荐的频率更频繁地重新开具处方。只有36%的支气管扩张剂使用者报告曾被告知要记录使用的pMDI剂量。其中,79%是由医生建议这样做的,6%是由药剂师建议的,3%是由护士建议的。在342名提到使用支气管扩张剂的受访者中,有87名(25%)报告在哮喘发作期间发现他们的pMDI是空的。其中7名患者不得不拨打911。在这87名患者中,71名(82%)在完全没有药物喷出时认为他们的pMDI是空的。
患者没有可靠的方法来监测其定量吸入器的药物含量,这导致了一些需要解决的严重问题。鉴于需要一种可靠的剂量计数方法,显然制造商应该将剂量计数器作为每个定量吸入器的标准配置。